Placental growth factor (PlGF) is an increasingly important molecule in the prediction,
diagnosis and treatment of pre-eclampsia. It has pro-angiogenic effects on the feto-placental …

BACKGROUND The placenta is the functional interface between the mother and the fetus
during pregnancy, and a critical determinant of fetal growth and life-long health. In the first …

Incomplete spiral artery remodelling is the first of two stages of pre-eclampsia, typically of
early onset. The second stage comprises dysregulated uteroplacental perfusion and …

Gestational Diabetes Mellitus (GDM) is a transitory metabolic condition caused by
dysregulation triggered by intolerance to carbohydrates, dysfunction of beta-pancreatic and …

During pregnancy, the mother's immune system has to tolerate the persistence of paternal
alloantigens without affecting the anti-infectious immune response. Consequently, several …

Elevated circulating sFLT-1 (soluble fms-like tyrosine kinase) and low levels of its ligand,
PlGF (placental growth factor), are key characteristics of preeclampsia. However, it is …

Preeclampsia is one of the most serious complications of pregnancy, affecting 5–10% of
parturients worldwide. Recent studies have suggested that autophagy is involved in …

Background The pathophysiology of preeclampsia is not clearly understood worldwide.
Hypoxia inducible factor 1α (HIF‐1α) is thought to be the preliminary factor for the hypoxic …

Objective CD248 is a transmembrane glycoprotein expressed on the surface of activated
perivascular and fibroblast‐like cells. This study was undertaken to explore the function of …

Objectives To assess levels of total placental growth factor (PlGF), soluble fms‐like tyrosine
kinase‐1 (sFlt‐1) and free PlGF in women with pre‐eclampsia (PE) with or without a small …